

Calgary Long Term Care Formulary
Pharmacy & Therapeutics
February 2019
Highlights

<https://www.albertahealthservices.ca/info/Page4071.aspx>

Contents

February 2019 3

 Formulary Changes (Additions, Changes, Deletions)..... 3

 Other Formulary Updates 3

November 2018 4

 Formulary Changes (Additions, Changes, Deletions)..... 4

 Other Formulary Updates 4

June 2018 5

 Formulary Changes (Additions, Changes, Deletions)..... 5

 Other Formulary Updates 5

March 2018 6

 Formulary Changes (Additions, Changes, Deletions)..... 6

 Other Formulary Updates 7

February 2019

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) were added to the Calgary Zone Long Term Care Formulary. When available, the lowest cost alternative (LCA) product is considered the benefit and should be dispensed.

Product Description	Strength	Dosage Form	Route of Administration	Listing/Comments
atropine sulfate	1%	drops	ophthalmic	re-added to Formulary
mupirocin	1%	ointment	topical	autosub changed from polysporin to fucidic acid
nitroglycerin (Nitrol®)	2%	ointment	topical	product discontinued

Other Formulary Updates

- **Formulary Policies and Procedures**
 - Correction to the Calgary Zone LTC [Wardstock and Statbox lists](#) (including Controlled Substances): the strength for hydromorphone tablets carried for stock should read 0.25 mg, not 0.5 mg.
- **Formulary Medication Listing**
 - [Full Formulary Listing](#) was updated
 - Reminders:
 - quetiapine 50 mg and 150 mg tablets are non-formulary
 - sotalol 80 mg is non-formulary
- **Automatic Substitution Lists**
 - [ASL-01 Automatic Substitution List –Miscellaneous](#) was updated

November 2018

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) were added to the Calgary Zone Long Term Care Formulary. When available, the lowest cost alternative (LCA) product is considered the benefit and should be dispensed.

Product Description	Strength	Dosage Form	Route of Administration	Listing/Comments
pyridoxine (vitamin B6)	50 mg, 100 mg	tablet	oral	Removed from Formulary (very low use/strength discontinued)
losartan	25 mg, 50 mg, 100 mg, 150 mg	tablet	oral	Added to Formulary and to Automatic Substitution List – ACE Inhibitors and ARBs (ASL-02)
enoxaparin	all strengths	pre-filled syringes	injection	Added to Formulary as High Cost Drugs (HCD-06)
dalteparin	3500 unit/syringe	pre-filled syringe	injection	Added to Formulary as High Cost Drug (HCD-06)
betamethasone dipropionate	0.05%	cream, ointment & lotion	topical	Added to Formulary and to Automatic Substitution List (ASL-01)
hydrocortisone 17-valerate	0.2%	cream and ointment	topical	Added to Formulary and to Automatic Substitution List (ASL-01)
clozapine	50 mg, 200 mg	tablet	oral	Added to Formulary as High Cost Drug (HCD-06)

Other Formulary Updates

- **Formulary Policies and Procedures**
 - Calgary Zone LTC [Wardstock and Statbox lists](#) (including Controlled Substances) were updated
- **Formulary Medication Listing**
 - [Full Formulary Listing](#) was updated
 - See above table with changes

- Reminders:
 - quetiapine 50 mg and 150 mg tablets are non-formulary
 - ramipril 15 mg tablets are non-formulary
- **Automatic Substitution Lists**
 - [ASL-01 Automatic Substitution List –Miscellaneous](#) was updated
 - [ASL-02 Automatic Substitution List -ACE Inhibitors and ARBS](#) was updated
- **Restricted Use Medications**
 - [Restricted Use Miscellaneous Drugs \(RS-11\)](#) was updated

June 2018

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) were added to the Calgary Zone Long Term Care Formulary. When available, the lowest cost alternative (LCA) product is considered the benefit and should be dispensed.

Product Description	Strength	Dosage Form	Route of Administration	Listing/Comments
atropine	1%	drops	ophthalmic	Removed from Formulary (product discontinued)
chlorhexidine compounded gel	0.12% - 1%	gel	oral	Added chlorhexidine compounded gel to Formulary. Removed restrictions
glycopyrrolate compounded suspension	0.5 mg/mL	suspension	oral	Added glycopyrrolate oral compounded suspension (using powder) to Formulary
metronidazole	1%	gel, cream	topical	Formulary listing for topical gel or cream changed from 0.75% to 1%
metronidazole	10%	cream	vaginal	Formulary listing for vaginal gel changed from 0.75% to 10%
mineral oil	heavy	liquid	for topical/otic use	Formulary listing changed from "light" to "heavy"

Other Formulary Updates Formulary

- Formulary Medication Listing –list updated
- Restricted Status
 - RS-11 Misc. –list updated to reflect chlorhexidine gel
 - RS-47 Metronidazole –list updated
- Automatic Substitution
 - ASL-01 –updates
 - Mineral oil, light (typically for otic use), will be auto-substituted to mineral oil, heavy. Mineral oil light is removed from Formulary
 - Cerumenex® will be auto-substituted to mineral oil, heavy.
 - Nifedipine 5 -10 mg will be auto-substituted to captopril 12.5 – 25 mg when ordered for hypertensive crisis.
 - Due to an intermittent manufacturer shortage of Lacri-lube®, as an alternate substitution for when it is not available, Systane® Lubricant eye ointment may be substituted.
 - Automatic substitution for metronidazole topical cream or gel changed to 1%
 - Automatic substitution for metronidazole vaginal cream changed to 10%

March 2018

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) were added to the Calgary Zone Long Term Care Formulary. When available, the lowest cost alternative (LCA) product is considered the benefit and should be dispensed.

Product Description	Strength	Dosage Form	Route of Administration	Listing/Comments
desmopressin acetate	10 mcg/dose	nasal spray	inhaled (nasal)	Strength updated in Formulary listing and RS-11 from 0.1mg/ml to 10mcg/dose.
insulin detemir (Levemir)	100 unit/mL	injectable	subcutaneous	Delisted from Formulary effective July 1, 2018.
insulin glargine (Basaglar)	100 unit/mL	injectable pre-filled pen	subcutaneous	Added to Formulary

insulin glargine (Lantus)	100 unit/mL	injectable pre-filled pen	subcutaneous	Moved from RS-44 to RS-11 RS-44 deleted. Transition period of 6 months (by Oct 1, 2018).
insulin human biosynthetic regular (Novolin ge Toronto)	100 unit/mL	injectable	subcutaneous	Delisted from Formulary effective July 1, 2018. Auto- substitution will apply (ASL-01)
insulin human biosynthetic isophane (Novolin ge NPH)	100 unit/mL	injectable	subcutaneous	
insulin human biosynthetic regular / insulin human biosynthetic isophane (Novolin ge 30/70)	30 unit/mL * 70 unit/mL	injectable	subcutaneous	
midazolam	5 mg/mL	injectable	subcutaneous	do not list –eligible for non- formulary review
morphine	2 mg/mL	injectable	subcutaneous	Added to Formulary Restricted Misc. (RS-11).

Other Formulary Updates

Contact Information

- **Long Term Care Providers**–list updated

Formulary

- Formulary Medication Listing –list updated
- Automatic Substitution
 - ASL-01 –updates
 - auto-substitution for Novolin ge Toronto, Novolin ge NPH and Novolin 30/70
 - Due to manufacturer shortage of amcinonide, betamethasone dipropionate 0.05% may be used as the auto-substitution for high potency corticosteroid creams/ointments or lotions in the interim.

- Clarification provided for auto-substitution PRN and daily use of diclofenac topical gels
- High Cost / Special Authorization
 - Influenza Antiviral Agents: Oseltamivir –updated
 - Oseltamivir (SA-03) –updated
 - Pregabalin (SA-28) –updated
 - Direct Oral Anticoagulants (SA-29) –new
- Restricted Use Medications
 - For all insulin products, the pre-filled disposable pens are considered the formulary listing. Insulin cartridges and vials are restricted to: a) a pre-filled pen is not available in the product line; or b) in situations where the LTC facility has approved the vial or cartridge as their site's preference through the site's P&T committee.
 - For all insulin products, resident-specific dispensing is preferred over supplying as wardstock. Any exceptions should be approved through the LTC facility's P&T committee.
 - RS-44 Basal Insulin (Glargine and Detemir) –deleted. Lantus continues to be restricted and its restriction can now be found in RS-11 Miscellaneous. Basaglar is added to the formulary without restrictions. Levemir will be de-listed effective July 1, 2018. It will be eligible for non-formulary review.

Antimicrobial Stewardship

- Under **Resources** –link to Spectrum provided

Education

- Under **Other Topics of Interest** –Proton Pump Inhibitor Deprescribing and References. Thank you to AHS Drug Utilization and Stewardship for preparing this Drug and Therapeutics Backgrounder and for permission to share with the Calgary Zone LTC Formulary program.